INARI MEDICAL INC (NARI) Forecast, Price Target & Analyst Ratings
NASDAQ:NARI • US45332Y1091
79.97 USD
+0.04 (+0.05%)
At close: Feb 18, 2025
79.98 USD
+0.01 (+0.01%)
After Hours: 2/18/2025, 8:00:58 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for INARI MEDICAL INC (NARI).
Forecast Snapshot
Consensus Price Target
$76.99
-3.73% Downside
Next Earnings Forecast
Release DateMar 4, 2025
PeriodQ4 / 2024
EPS Estimate$0.01
Revenue Estimate163.82M
ChartMill Buy Consensus
77.27%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$76.99
Upside
-3.73%
From current price of $79.97 to mean target of $76.99, Based on 22 analyst forecasts
Low
$50.50
Median
$81.60
High
$84.00
Price Target Revisions
1 Month
12.89%
3 Months
17.02%
Price Target Summary
22 Wall Street analysts provided a forecast for the next 12 months for NARI. The average price target is 76.99 USD. This implies a price decrease of -3.73% is expected in the next year compared to the current price of 79.97.
The average price target has been revised upward by 17.02% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
77.27%
NARI was analyzed by 22 analysts. The buy percentage consensus is at 77. So analysts seem to be have mildly positive about NARI.
In the last month the buy percentage fell by 5 points. So the trust of analysts is decreasing.
NARI was analyzed by 22 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-01-08 | BTIG | Downgrade | Buy -> Neutral |
| 2025-01-07 | William Blair | Downgrade | Outperform -> Market Perform |
| 2025-01-07 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2025-01-07 | Baird | Downgrade | Outperform -> Neutral |
| 2025-01-07 | Canaccord Genuity | Downgrade | Buy -> Hold |
| 2025-01-07 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2024-12-18 | Truist Securities | Maintains | Hold -> Hold |
| 2024-12-17 | Oppenheimer | Initiate | Outperform |
| 2024-10-30 | Needham | Reiterate | Hold |
| 2024-10-29 | Needham | Reiterate | Hold |
| 2024-10-29 | Truist Securities | Maintains | Hold -> Hold |
| 2024-10-29 | Baird | Maintains | Outperform -> Outperform |
| 2024-10-29 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-10-29 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2024-10-14 | Truist Securities | Maintains | Hold -> Hold |
| 2024-10-09 | Needham | Reiterate | Hold |
| 2024-09-17 | Stifel | Initiate | Hold |
| 2024-09-03 | Leerink Partners | Initiate | Market Perform |
| 2024-08-26 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2024-08-09 | Deutsche Bank | Initiate | Buy |
| 2024-07-31 | Needham | Reiterate | Hold |
| 2024-07-31 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-07-31 | Truist Securities | Reiterate | Hold -> Hold |
| 2024-07-31 | Baird | Maintains | Outperform -> Outperform |
| 2024-07-31 | Canaccord Genuity | Maintains | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 4, 2025
PeriodQ4 / 2024
EPS Estimate$0.01
Revenue Estimate163.82M
Revenue Q2Q24.02%
EPS Q2Q106.52%
Number of Analysts17
Next Earnings Revisions
Revenue (1 Month)
-0.01%
Revenue (3 Months)
0.07%
EPS (1 Month)
250.29%
EPS (3 Months)
250.29%
Next Earnings Summary
NARI is expected to report earnings on 3/4/2025. The consensus EPS estimate for the next earnings is 0.01 USD and the consensus revenue estimate is 163.82M USD.
The next earnings revenue estimate has been revised upward by 0.07% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 277M 98.28% | 383.5M 38.45% | 493.632M 28.72% | 615.15M 24.62% | 725.85M 18.00% | 846.21M 16.58% | 1.005B 18.76% | 1.124B 11.84% | 1.276B 13.52% | 1.224B -4.08% | |
| EBITDA YoY % growth | 13.83M -31.16% | -23.43M -269.41% | 3.258M 113.91% | -29.641M -1,009.80% | 27.908M 194.15% | 54.593M 95.62% | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | 10.8M -42.25% | -28.1M -360.19% | -3.632M 87.07% | -28.224M -677.09% | 9.512M 133.70% | 36.661M 285.42% | 61.506M 67.77% | 109.24M 77.61% | 185.54M 69.85% | N/A | |
| Operating Margin | 3.90% | -7.33% | -0.74% | -4.59% | 1.31% | 4.33% | 6.12% | 9.72% | 14.54% | N/A | |
| EPS YoY % growth | 0.16 -27.27% | -0.55 -443.75% | -0.03 94.55% | -0.78 -2,492.94% | 0.20 125.35% | 0.68 245.15% | 0.95 39.37% | 1.53 61.29% | 2.45 60.00% | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.01 106.52% | -0.02 91.76% | 0.02 106.26% | 0.08 191.92% | 0.11 2,101.57% | 0.04 324.97% | 0.06 157.18% | 0.07 -13.70% | 0.10 -11.11% |
| Revenue Q2Q % growth | 163.82M 24.02% | 172.16M 20.23% | 175.41M 20.29% | 184.33M 20.17% | 193.61M 18.18% | 207.57M 20.57% | 213.08M 21.48% | 223.99M 21.52% | 235.42M 21.59% |
| EBITDA Q2Q % growth | 4.273M -46.54% | 1.21M 111.49% | 4.408M 132.26% | 6.418M 571.57% | 9.412M 120.27% | 3.876M 220.33% | 5.916M 34.21% | 6.732M 4.89% | 8.772M -6.80% |
| EBIT Q2Q % growth | -1.015M -192.06% | -2.083M 85.53% | 1.07M 105.00% | 4.299M 132.47% | 6.516M 741.71% | -102K 95.10% | 1.836M 71.59% | 2.55M -40.68% | 4.59M -29.56% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
191.18%
EPS Next 5 Year
121.24%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
18.92%
Revenue Next 5 Year
17.44%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
107.80%
EBIT Next 5 Year
N/A
INARI MEDICAL INC / NARI Forecast FAQ
What is the price target for NARI stock?
22 analysts have analysed NARI and the average price target is 76.99 USD. This implies a price decrease of -3.73% is expected in the next year compared to the current price of 79.97.
What is the next earnings date for NARI stock?
INARI MEDICAL INC (NARI) will report earnings on 2025-03-04, after the market close.
What are the consensus estimates for NARI stock next earnings?
The consensus EPS estimate for the next earnings of INARI MEDICAL INC (NARI) is 0.01 USD and the consensus revenue estimate is 163.82M USD.
What is the consensus rating for INARI MEDICAL INC (NARI) stock?
The consensus rating for INARI MEDICAL INC (NARI) is 77.2727 / 100 . This indicates that analysts generally have a positive outlook on the stock.